The hypothesis of targeting inflammation to stabilize plaque and thereby prevent cardiovascular events has apparently been confirmed in top-line data from Novartis AG's 10,000-patient CANTOS Phase III study of its IL-1β inhibitor antibody ACZ885 (canakinumab) in atherosclerosis.
The unexpected news – that the study measured over three years had met its primary endpoint of reducing the risk...







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)